Last reviewed · How we verify
Daratumumab SC (Darzalex) (daratumumab-sc-darzalex)
At a glance
| Generic name | daratumumab-sc-darzalex |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 3 |
Approved indications
Common side effects
- Neutropenia
- Anaemia
- Thrombocytopenia
- Diarrhoea
- Fatigue
- Constipation
- Nausea
- Insomnia
- Pyrexia
- Asthenia
- Cough
- Peripheral Sensory Neuropathy
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daratumumab SC (Darzalex) CI brief — competitive landscape report
- Daratumumab SC (Darzalex) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI